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Abstract 
Ovulation monitors are widely used by women wishing to achieve pregnancy. However, there are 
few data substantiating claims that these devices enhance the probability of becoming pregnant. In 
one report it is concluded from the cumulative pregnancy rate that the use of the Clearblue Easy 
Fertility Monitor increased the pregnancy rate. In a second report, it is argued that the use of the 
Clearblue Digital Ovulation Test reduces the time taken to conceive. We reconsider these previously 
published data by analysing each cycle and show that use of such devices might have a small effect 
(ϕ ≈ 0.12, odds ratio = 2.1-2.2, relative risk = 1.9) in the first month of use, but has no significant 
effect (ϕ ≈ 0.01, odds ratio = 1.2, relative risk = 1.1-1.2) in the second month. However, the subjects 
recruited for these two trials had single cycle pregnancy rates (7-11%) that were more similar to those 
of women avoiding pregnancy (about 6%) than women trying to conceive (about 25%). Given this, 
there is a reason to suspect that the data that are available might not be representative of all women. 
Further work is required to test whether even this small transient effect can be replicated in women 
with higher pregnancy rates. Women should be aware of the limitations of these ovulation monitors. 
Keywords: Fertility; Menstrual cycle; Ovulation monitor; Pregnancy 
Introduction 
Ovulation monitors are used by many women to support their efforts to avoid or become 
pregnant. The basis of this is that a woman is usually fertile for a few days during each menstrual 
cycle and this 'fertile window' can be identified using the device. In some trials, ovulation monitors 
have been employed in the contraceptive mode as the only method used [1, 2], despite warnings from 
health authorities [3], and in others, they have been combined with various fertility awareness 
methods [4, 5]. Robinson et al. [6] provide data for just two cycles, these parameters can only be 
estimated algebraically (Appendix).  This approach yields π ≈ 0.15 and P(∞) ≈ 0.51, both of which 
are lower than any of the corresponding values for other reports. While these values are not 
particularly reliable as they are based on only two cycles, it does provide some indication of what 
might be expected had Robinson et al. [6] continued to monitor their subjects for more cycles. Some 
weak support for the low P(∞) estimated from these data is provided by the results of Zinaman et al. 
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[16] who recruited subjects wishing to conceive in a similar way using the same manufacturer's 
website. As it was conducted for a different purpose, that study did not include a control group of 
subjects who did not use an ovulation monitor. Nevertheless, only 42% of these subjects had 
conceived after six cycles, despite using an ovulation monitor to assist them. This is more than the 
32% estimated from the data of Robinson et al. [6] but is much smaller than the 75% after six cycles 
reported by Wilcox et al. [24]. That both parameters were so much smaller prompts the speculation 
that not only was the probability of pregnancy of the subjects decreased (π ≈ 0.15 versus π = 0.35), 
but the proportion of women unlikely to conceive was increased (P(∞) ≈ 0.51 versus P(∞) = 0.82). 
We do not pretend that there is a reliable statistical basis for these speculations, but it does seem likely 
that the subjects recruited for the work of Robinson et al. [6] were not necessarily representative of 
women in general. What the use of an ovulation monitor enhances the probability of becoming 
pregnant [6], in part, it is argued, because couples mistime coitus if they do not know when the 
woman is fertile [7]. The timing of intercourse is important because the ovum is viable for only 8-12 
hours after ovulation, so the window of opportunity is quite brief.  As the manufacturer's current 
advertising appears to emphasize pregnancy achievement, which is of particular importance to many 
women [8], and because these devices are relied on by many women who can incur significant 
financial cost [7], we consider this application of ovulation monitors. 
Some ambiguity arises when comparing some of the devices because they have been available for 
sale with various product names for more than two decades [9-11], but the hormones measured seem 
to have been consistent. The current tests employ urinary measurements of two reproductive 
hormones (luteinizing hormone (LH) and the oestradiol metabolite oestrone-3-glucuronide (E1-3G)) 
to identify days of 'high fertility' during the menstrual cycle. Neither the details of the measurements 
nor the algorithm used to interpret the data has been published except, in very general terms, in a 
patent. However, these two hormones (LH and E1-3G) can if measured appropriately, provide 
information about the onset of fertility and the day of ovulation, but they do not give consistently 
reliable information about the end of the fertile period [12, 13]. 
We use the available published data [6, 14] to investigate how well they substantiate the claim that 
the use of an ovulation monitor enhances a woman's chance of becoming pregnant.  While several 
trials of ovulation monitors are registered, the data are not (yet) available from the CDC trial database. 
In these circumstances, the usefulness of these devices can only be judged from the published reports.  
Material and Method 
The data used are those of Jones et al. [14] and Tiplady et al. [15] who report on the same trial of 
the Clearblue Digital Ovulation Test (CDOT) and Robinson et al. [6] who stated on a trial of the 
Clearblue Easy Fertility Monitor (CEFM). We have been unable to identify any other reports of 
comparable trials, but we make a brief reference to an uncontrolled trial of the Clearblue Fertility 
Monitor that was conducted for different purposes [16]. It is not clear whether the different product 
names represent substantive differences in the method or commercial expedience, so caution should 
be exercised in making direct comparisons of the data. All calculations were carried out using R and, 
where appropriate, the exact 2×2 package [17, 18]. The power of a statistical test depends mostly on 
the sample size and the effect size [19, 20]. For example, even a small effect might be statistically 
significant if the sample size is large, but an effect of that magnitude might be of little practical use.  
On the other hand, a practically significant effect may or may not be observed by chance. Given this, 
we report both the statistical significance and several measures of the effect size. While the numbers 
specified differ, as a guide, the odds ratio can be considered small, medium or large if it is 1.5, 2 or 4, 
respectively, [19] and ϕ can be considered small, medium or large if it is 0.2, 0.4 or 0.6, respectively 
[20]. The confidence intervals for ϕ [21] were determined using 1000 bootstrap replicates rather than 
the theoretical expression [22]. 
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Results and Discussion 
The Clearblue Easy Fertility Monitor (CEFM) Trial 
Robinson et al. [6] enrolled 1000 women in a trial of the CEFM. After excluding nine women who 
became pregnant before the trial began, 335 women who did not respond and five women who did 
not match the selection criteria, 309 women were assigned to a group using CEFM and 348 women 
to a control group that did not use CEFM. Four women (three CEFM users and one non-user) were 
excluded at the end of the first cycle because they provided no data.  During the first cycle, 46 CEFM 
users and 27 non-users became pregnant. At the end of the trial, after two menstrual cycles, data were 
available from 302 and 347 women among the CEFM users and non-users, respectively. The number 
of women becoming pregnant during the second cycle is not stated. However, it can be estimated by 
subtracting the number of pregnancies in the first cycle from the total number at the end of the trial.  
By the end of the trial 22.7% of 305 CEFM users and 14.4% of 348 non-users had become pregnant, 
which corresponds to 69 (≈ 0.227 × 305) and 50 (≈ 0.144 × 348) pregnancies, respectively.  If these 
numbers are correct then 23 (= 69 – 46) CEFM users and 23 (= 50 – 27) non-users became pregnant 
during the second cycle. In Table 1 the data are summarised for each cycle, following the approach 
of Wilcox et al. [23, 24], rather than presenting the cumulative data as Robinson et al. [6] did. 
The data in Table 1 indicate that Robinson et al. [6] observed a small (ϕ = 0.11), but significant (p 
= 0.004), effect in the first cycle.  However, there was no significant effect (ϕ = 0.02, p = 0.617) in 
the second cycle.  In the first cycle, the relative pregnancy rate associated with CEFM use was 1.9, 
indicating that the device did not quite double a woman's chance of becoming pregnant on average, 
and was only 1.2 [95% CI: 0.7, 2.1] in the second cycle. Note that the probability of pregnancy among 
non-users in this trial was less than 0.08 in both cycles (Table 1). 
Table 1. Summary of the single cycle data of Robinson et al. [6] and Jones et al. [14] for users of 
CEFM and CDOT, respectively. The ranges in square brackets are 95% confidence intervals. 
 Robinson et al. [6] Jones et al. [14] 
 cycle 1 cycle 2 cycle 1 cycle 2 
Non-users 
Entering cycle 348 320 82 54 
Pregnancies 27 23* 9 6 
Exclusions 1 0 19 5 
Pregnancy rate (%) 7.8 [5.2, 11.1] 7.2 [4.6, 10.6] 11.0 [5.1, 19.8] 11.1 [4.2, 24.5] 
Users 
Entering cycle 305 266 93 55 
Pregnancies 46 23* 20 7 
Exclusions 3 0 18 4 
Pregnancy rate (%) 15.1 [11.2, 19.6] 8.6 [5.5, 12.7] 21.5 [13.6, 31.2] 12.7 [5.3, 24.5] 
     
odds ratio 2.1 [1.3, 3.6] 1.2 [0.6, 2.3] 2.2 [0.9, 5.5] 1.2 [0.3, 3.9] 
relative rate 1.9 [1.2, 3.0] 1.2 [0.7, 2.1] 1.9 [0.9, 4.0] 1.1 [0.4, 3.2] 
χ2  8.06 (p = 0.004) 0.25 (p = 0.617) 2.8 (p = 0.096) 0.0 (p = 1.000) 
ϕ 0.11 [0.03, 0.18] 0.02 [0.00, 0.10] 0.12 [0.00, 0.26] 0.00 [0.00, 0.19] 
ϕ/ϕmax  0.17  0.04 0.16 0.00 
* An estimate that is explained in the text. 
 
The Clearblue Digital Ovulation Test (CDOT) Trial 
Jones et al. [14] enrolled 210 women who wished to become pregnant in a trial of the CDOT.  The 
women were randomly assigned to either a group using CDOT or a control group that did not use 
any fertility awareness aids (such as observations of basal body temperature or cervical mucus).  By 
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the start of the trial 35 women had become pregnant and were excluded from further participation, 
leaving 93 and 82 women in the CDOT and control groups, respectively.  Both groups were followed 
for two menstrual cycles.  At the end of the first cycle, 20 women in the CDOT group and 9 women 
in the control group had become pregnant.  At the end of the second cycle, 27 of the women 
remaining in the CDOT group and 15 of the women remaining in the control group had become 
pregnant.  Unlike Robinson et al. [6], Jones et al. [14] are explicit about the number of pregnancies 
and the data for each cycle are summarised in Table 1. 
In this case, the use of CDOT had no statistically significant effect on the probability of pregnancy 
(p = 0.096 and p = 1.000 in cycles one and two, respectively (Table 1)).  Nevertheless, the odds ratio, 
relative risk and ϕ were similar to the corresponding measures reported for CEFM, which might 
indicate some similarity between the two devices.  The lack of significance in this trial is probably due 
to the smaller number of subjects (Table 1).  For example, assuming type 1 and type 2 error rates of 
α = 0.95 and β = 0.8, respectively, standard power analysis [25] indicates that 255 subjects (without 
accounting for attrition) are required to detect a difference of 10.5% in the pregnancy rate.  It is, 
perhaps, unfair to observe that the same calculation for cycle two indicates that about 8500 subjects 
are required to detect a difference of 1.6% of the pregnancy rate. This simply reinforces the small 
effect on the probability of pregnancy associated with the use of such ovulation monitors. 
Discussion 
The data show that the use of an ovulation monitor may have a small effect in the first cycle, but 
that it has no effect in the second cycle (Table 1). By reporting the cumulative pregnancy rate rather 
than the rate for each cycle, Robinson et al. [6] made the difference between the first and second 
cycles less apparent. Women contemplating the use of these ovulation monitors to assist them to 
conceive should be aware of this. 
It might be argued that it is inevitable in a trial like this that the pregnancy rate would decline as 
the trial progresses. This is correct, but a decline to the control rate (about 8%) in the proportion of 
women conceiving after a single cycle is unexpected.  In work involving fewer subjects, Wilcox et al. 
[23, 24] observed a higher pregnancy rate (about 25%) which was maintained for the first three cycles 
before a gradual decline. The pattern in the data of Robinson et al. [6] is quite different. Tiplady et al. 
[15], working with the same data as Jones et al. [14], employed Kaplan-Meier analysis and concluded 
that a "possible reduction in time to pregnancy" was associated with the use of CDOT, although this 
became "did not negatively affect time to conception" in the abstract.  The simple analysis employed 
here makes the point very clearly: in the CDOT trial there was no significant effect in either cycle, 
and in the much larger CEFM trial there was no significant effect in the second cycle. 
A second concerning feature of the data is that the pregnancy rates among the non-user control 
groups are low in both trials (Figure 1).  The control group pregnancy rate reported by Robinson et 
al. [6] is only 7.8% in the first cycle and, based on the foregoing calculations, 7.2% in the second 
cycle. This is much lower than the corresponding rates for women who wanted to become pregnant 
(about 24.0% [95% CI: 18.5% to 30.2%] and 25.5% [18.9% to 32.9%] in cycles one and two, 
respectively, of their trial) reported by Wilcox et al. [23, 24] (Figure 1) and others in which the mean 
cycle one rates range from 29% to 38% [26-28]. None of these latter rates is significantly different 
from the rates observed arising from coitus during the fertile period by Barrett and Marshall [29]. On 
the other hand, Robinson's control group rates are similar to the overall single cycle rate reported by 
Barrett and Marshall [29] for women who wished to avoid pregnancy (6.6% [6.0% to 7.3%]) and to 
the value specified by Evers [30] as characteristic of 'moderately subfertile' women. In contrast, the 
control group pregnancy rate of Jones et al. [14] is about 11% for each cycle which is not significantly 
different from either the rate reported by Wilcox et al. [24] for either of the first two cycles (p ≥ 0.135) 
or the control group rates of Robinson et al. [6] (Figure 1). The subjects recruited through the 
company website [6, 14] appear to have differed materially from those recruited through newspaper 
advertisements 30 years earlier by Wilcox et al. [23, 24]. Further work is required to determine whether 
the small effect demonstrated in cycle one of the CEFM trial can be expected from other cohorts of 
women. 
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Figure 1. The probability of pregnancy in a cycle of women not using an ovulation monitor.  The 
data (and 95% confidence intervals) are those of Barrett and Marshall [29] for women avoiding 
pregnancy (Barrett), Wilcox et al. [24] for the first two cycles of women who did wish to become 
pregnant (Wilcox) and for both cycles in each of the trials of Robinson et al. [6] and Jones et al. [14]. 
The grey zones represent the 95% confidence intervals for the average probability (indicated by the 
dashed lines) based only on days in (upper zone) or outside (lower zone) the fertile period (days -5 
to +1 relative to ovulation) calculated from the data of Barrett and Marshall [29].  The horizontal 
solid lines are the maximum and minimum daily probability of pregnancy reported by Barrett and 
Marshall [29] the larger of which is very similar to the value Gnoth et al. [27] give for the single 
cycle pregnancy rate of 'truly fertile' couples. 
The differences in the probability of pregnancy shown in Figure 1 are compounded over time 
(Figure 2). According to several reports, the cumulative probability of pregnancy increases from about 
30% in the first cycle and exceeds 80% within about ten cycles [24, 26, 27] (Figure 2). If the probability 
of pregnancy in a cycle (π) is constant and the cycles are independent, then the probability that women 
do not conceive (1 - π) in n - 1 cycles and then do (π) in the nth cycle is 




P pregnancy in cycle 1
n
n   (1)  
and the corresponding cumulative probability function is 
         
1
P P pregnancy in  cycles 1 1 1 1
n n
n n      

             (2)  
[31]. However, only a fraction (P(∞)) of women can conceive, so a more realistic expression for the 
cumulative probability of pregnancy in n cycles or fewer is 
      P P 1 1 nn      (3)  
In this case, the probability of pregnancy in cycle one is just P(1) = πP(∞), so π ≥ P(1 ). This can be 
tested by applying (3) to data reported in the literature. For this purpose, we take the data of Wilcox 
et al. [24] as a reference because (a) only 5% of their subjects had been taking oral contraceptives, 
which are known to extend slightly the time required to conceive after ending their use [32], before 
the monitoring began, (b) their age range is similar to that of subjects involved in the CEFM trial 
(Table 2) and (c) their subjects were monitored for nine cycles. For these data π = 0.35 ± 0.04 (95% 
CI) and P(∞) = 0.80 ± 0.04 (95% CI), from which the probability of pregnancy in cycle one is πP(∞) 
≈ 0.28 and about 18% of women are unlikely to conceive (Figure 2).  The values of π obtained using 
the data of Wang et al. [28] and Zinaman et al. [26] are not significantly different from π = 0.35 (p ≥ 
0.284), but a lower value (p < 0.001) is obtained for women who had recently stopped taking oral 
contraceptives [33] (Table 2), consistent with their known effect in some women [32]. Similarly, the 
values of P(∞) were not significantly different from 0.80 (p ≥ 0.211), except for the examples of 
Wiegratz et al. [33] and Wang et al. [28] (p < 0.001). It is not clear why this is the case for the former. 
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In the latter case, women over the age of 34 and any woman who had tried unsuccessfully to get 
pregnant for at least a year at any time were specifically excluded. As almost all of their subjects 
conceived within ten cycles, P(∞) = 0.99. 
 
Figure 2. Cumulative probability of pregnancy of subjects not using an ovulation monitor.  The 
data shown are those of Gnoth et al. [27] (◊), Wilcox et al. [24] (○), Zinaman et al. [26] (□), and 
Robinson et al. [6] (●). The error bars are 95% confidence intervals.  The upper curve is a fit of (3) 
to the data of Wilcox et al. [24]. The lower curve is the algebraically estimated (Appendix) fit of (3) 
to the data of Robinson et al. [6] and the grey zone represents an estimate of the uncertainty based 
on that of the reported data. Note that the dashed curve section of each curve represents 
extrapolation. Details of the parameter estimates are given in Table 2. 
Table 2. Estimates (± 95% CI) of π and P(∞) obtained from data discussed in the text and some of 
the relevant details of the subjects.  Some of the data are plotted in Figure 2. 
Source Subjects* n π P(∞) 
Gnoth et al. [27] 20-44 y, using NFP to time intercourse 340 0.39 0.89 
Robinson et al. [6] 21-40 y, excluded if had been trying to 
conceive for more than 2 y, not using 
ovulation monitor 
348 0.15 0.51 
Wang et al. [28] 20-34 y, excluded if had ever tried 
unsuccessfully to conceive for more than 1 
y 
518 0.33 ± 0.01 0.99 ± 0.01 
Wiegratz et al. [33] 16-41 y, based on time from ending oral 
contraceptive use 
706 0.24 ± 0.02 0.90 ± 0.03 
Wilcox et al. [24] 21-42 y, 5% of subjects ended use of oral 
contraceptives when trial began 
221 0.35 ± 0.04 0.80 ± 0.04 
Zinaman et al. [26] 21-37 y, from 0-5 months of ending 
contraceptive use, type of contraceptive not 
specified 
200 0.36 ± 0.02 0.82 ± 0.01 
* NFP is natural family planning 
 
As Robinson et al. [6] provide data for just two cycles, these parameters can only be estimated 
algebraically (Appendix). This approach yields π ≈ 0.15 and P(∞) ≈ 0.51, both of which are lower 
than any of the corresponding values for other reports. While these values are not particularly reliable 
as they are based on only two cycles, it does provide some indication of what might be expected had 
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Robinson et al. [6] continued to monitor their subjects for more cycles. Some weak support for the 
low P(∞) estimated from these data is provided by the results of Zinaman et al. [16] who recruited 
subjects wishing to conceive in a similar way using the same manufacturer's website.  As it was 
conducted for a different purpose, that study did not include a control group of subjects who did not 
use an ovulation monitor. Nevertheless, only 42% of these subjects had conceived after six cycles, 
despite using an ovulation monitor to assist them. This is more than the 32% estimated from the data 
of Robinson et al. [6] but is much smaller than the 75% after six cycles reported by Wilcox et al. [24] 
(Figure 2). That both parameters were so much smaller prompts the speculation that not only was 
the probability of pregnancy of the subjects decreased (π ≈ 0.15 versus π = 0.35), but the proportion 
of women unlikely to conceive was increased (P(∞) ≈ 0.51 versus P(∞) = 0.82). We do not pretend 
that there is a reliable statistical basis for these speculations, but it does seem likely that the subjects 
recruited for the work of Robinson et al. [6] were not necessarily representative of women in general 
(Figures 1 and 2). 
Finally, we note that Gnoth et al. [27], reporting on the use of natural family planning techniques 
to help couples improve the timing of intercourse, presented data from which it can be estimated 
that π ≈ 0.39 and P(∞) ≈ 0.89 (Table 2). Unfortunately, they employed no control group, but it is 
interesting to observe that the cumulative pregnancy rates they report are consistently greater over 
12 cycles than those of Wilcox et al. [24] and Zinaman et al. [26] (Figure 2). We cannot know whether 
a control group might have yielded data closer to those of Wilcox et al. [24] and Zinaman et al. [26], 
but it is tempting to speculate that women wishing to conceive might be advantaged by using the 
techniques described by Gnoth et al. [27] rather than an ovulation monitor.  More work on these 
important issues is warranted [12, 13, 34]. The published data indicate that ovulation monitors have 
limitations that should be made clear to potential users. 
Conclusions 
The published data underpinning two ovulation monitors promoted for use by women wishing 
to become pregnant indicate that their use (a) does not affect a woman's chances of becoming 
pregnant, or, if it does, that that effect is small (ϕ ≈ 0.1) and (b) appears to be limited to the first 
cycle of use. In the one trial in which the use of an ovulation monitor has been shown to have a 
statistically significant effect in one cycle, the control pregnancy rate was closer to that of women 
wishing to avoid pregnancy than those wishing to achieve it. In that case, the effect was to change 
the rate for a single cycle from about 7.8% to 15.1 %. Whether the same small improvement in one 
cycle could be expected for women has not been established.   
Appendix. Algebraic parameter estimates 
Robinson et al. [6] provide data for only two cycles ((n1, P1), (n2, P2), where the ni ≥ 1 are the cycle 
numbers and 0 ≤ Pi ≤ 1 are the corresponding observed cumulative probabilities), so the parameters 
of (3) can be determined by substituting the data into (3) to obtain  
    11P P 1 1 n     and     22P P 1 1 n     (A1)  
Eliminating P(∞) from these expressions yields a polynomial in (1 - π) 
   1 22 1 1 2P 1 P 1 P P 0
n n
         (A2)  
which can be solved for (1 - π). The corresponding estimate for P(∞) can be found by substituting 
the solution into one of the expressions in (A1).  One solution of (A2) is (1 - π) = 1 (or π = 0), as can 
be found by inspection, but this can be discounted because it is inconsistent with the data.  For the 
particular case in Robinson et al. [6], n1 = 1 and n2 = 2, so the other solution of (A2) is (1 - π) = (P2 - 
P1)/P1, which yields π = 2 - (P2/P1) and P(∞) = P1/π = P12/(2P1 - P2). 
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List of abbreviations  
CDOT Clearblue Digital Ovulation Test 
CEFM Clearblue Easy Fertility Monitor 
E1-3G oestrone-3-glucuronide  
LH  luteinizing hormone 
ni  number of the ith cycle 
Pi  observed probability of pregnancy by the ith cycle 
P(n)  theoretical estimate of the probability of pregnancy by the nth cycle 
P(∞) theoretical estimate of the fraction of women capable of conceiving 
π  probability of pregnancy in a cycle 
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